Arsenic trioxide mechanisms of action – looking beyond acute promyelocytic leukemia
- 1 January 2008
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10) , 1846-1851
- https://doi.org/10.1080/10428190802464745
Abstract
(2008). Arsenic trioxide mechanisms of action – looking beyond acute promyelocytic leukemia. Leukemia & Lymphoma: Vol. 49, No. 10, pp. 1846-1851.This publication has 53 references indexed in Scilit:
- Catalase activity and arsenic sensitivity in acute leukemiaLeukemia & Lymphoma, 2008
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004
- Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignanciesCancer, 2004
- Apoptosis and leukaemiaBritish Journal of Haematology, 2003
- Inhibition of Mitochondrial RespirationJournal of Biological Chemistry, 2003
- Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agentsBlood, 2003
- Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor α Oncoprotein Found in Human Acute Promyelocytic LeukemiaMolecular and Cellular Biology, 2001
- Arsenic Trioxide Induces G2/M Growth Arrest and Apoptosis after Caspase-3 Activation and Bcl-2 Phosphorylation in Promonocytic U937 CellsBiochemical and Biophysical Research Communications, 2001
- Arsenite Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition PoreExperimental Cell Research, 1999
- REDOX REGULATION OF CELLULAR ACTIVATIONAnnual Review of Immunology, 1997